Drugs / GC007g
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04516551 | Nov 2020 → Dec 2021 | B-cell acute lymphoblastic leukemia, adult acute lymphoblastic leukemia | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-05-11 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Results Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress gracellbio.com ↗
The data showcases a 100% ORR and will be presented on Friday, June 9, 6:00 – 7:00 PM CEST. |
| 2021-01-13 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Regulatory China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL gracellbio.com ↗
The approval of the pivotal study for GC007g is an exciting milestone for the program |
| 2020-04-03 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Regulatory Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia gracellbio.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC007g | “This phase 1 clinical trial aims to evaluate safety and efficacy of donor-derived anti-CD19 CAR T cells (GC007g) in B-ALL patients who relapsed after allo-HSCT.” PMID 38204488 ↗ Dec 2023 |
| Modality | Cell therapy | “chimeric antigen receptor-modified T cells (CAR T) cell therapy” PMID 38204488 ↗ Dec 2023 |